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mir-34a and DAPK1 in chronic lymphocytic
leukemia
Lu Qian Wang1, Yok Lam Kwong1, Kit Fai Wong2, Chi Shan Bonnie Kho3, Dong Yan Jin4, Eric Tse1,
Anders Rosèn5 and Chor Sang Chim1*Abstract
Background: TP53 mutation/deletion is uncommon in chronic lymphocytic leukemia (CLL). We postulated that
components of TP53-centered tumor suppressor network, miR-34b/c, in addition to DAPK1 and miR-34a might be
inactivated by DNA hypermethylation. Moreover, we tested if miR-34b/c methylation might correlate with miR-203
or miR-124-1 methylation in CLL.
Methods: miR-34b/c, miR-34a and DAPK1 methylation was studied in 11 normal controls, 7 CLL cell lines, and 78
diagnostic CLL samples by methylation-specific polymerase chain reaction. MEC-1 cells were treated with
5-Aza-2’-deoxycytidine for reversal of methylation-associated miRNA silencing. Tumor suppressor properties of
miR-34b were demonstrated by over-expression of precursor miR-34b in MEC-1 cells.
Results: miR-34b/c promoter was unmethylated in normal controls, but completely methylated in 4 CLL cell lines.
miR-34b/c expression was inversely correlated with miR-34b/c methylation. Different MSP statuses of miR-34b/c,
including complete methylation and complete unmethylation, were verified by quantitative bisulfite pyrosequencing.
5-Aza-2’-deoxycytidine treatment resulted in promoter demethylation and miR-34b re-expression in MEC1 cells.
Moreover, over-expression of miR-34b resulted in inhibition of cellular proliferation and increased cell death. In
primary CLL samples, miR-34a, miR-34b/c and DAPK1 methylation was detected in 2.6%, 17.9% and 34.6% of patients at
diagnosis respectively. Furthermore, 39.7%, 3.8% and 2.6% patients had methylation of one, two or all three genes
respectively. Overall, 46.2% patients had methylation of at least one of these three genes. Besides, miR-34b/c
methylation was associated with methylation of miR-34a (P = 0.03) and miR-203 (P = 0.012) in CLL.
Conclusions: Taken together, miR-34b/c is a tumor suppressor miRNA frequently methylated, and hence silenced in
CLL. Together with DAPK1 methylation, miR-34b/c methylation is implicated in the disruption of the TP53-centered
tumor suppressor network. Moreover, the association of miRNA methylation warrants further study.
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DNA methylation refers to the chemical modification of
the cytosine ring in a CpG dinucleotide by the addition of
a methyl group (−CH3) to the 5-carbon position of the
cytosine pyrimidine ring in DNA, leading to the formation
of 5-methylcytosine (5meC) [1]. Global DNA hypomethy-
lation and aberrant, locus-specific DNA methylation of* Correspondence: jcschim@hku.hk
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genes (TSGs) are the hallmarks of many human cancers
[2-4]. It has been reported that methylation of TSG results
in dysregulation of the cell cycle (CDKN2A/B), apoptosis
(DAPK1/CDKN2A/APAF1), WNT (soluble WNT inhi-
bitors) and JAK/STAT signaling (SOCS1 and PTPN6) in
leukemia, lymphoma and myeloma, suggesting that
TSG methylation plays an important role in the pa-
thogenesis of various hematological cancers [5-8]. In
chronic lymphocytic leukemia (CLL), TSGs includingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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rantly methylated (hypermethylated) [9-11].
Mature microRNA (miRNAs) are a class of endogen-
ous, single-stranded, non-protein-coding small RNAs
measuring 19 to 25 nucleotides (nts), which are respon-
sible for the downregulation of targeted protein [12,13].
miRNAs involved in carcinogenesis may be either onco-
genic (oncomirs) or tumor suppressive [14]. Recently,
tumor suppressive miRNAs have also shown to be si-
lenced by aberrant DNA methylation in cancers [1].
Recently, DNA methylation of miR-34b/c has been
demonstrated in colorectal cancer, lung cancer and acute
lymphoid leukemia. miR-34b/c, like miR-34a, is under
the transcriptional regulation of TP53. TP53 inactivation,
mostly via mutations, occurs in up to 50% epithelial can-
cers at diagnosis [15,16]. In contrast, TP53 mutation or
del (17p) is only found in only 5% to 10% of CLL pa-
tients at diagnosis [17-19]. Therefore, other mechanisms
leading to TP53 malfunction may exist. In this connec-
tion, methylation of DAPK1 gene, which triggers TP53
activation upon oncogenic cellular transformation, was
first reported as a TSG methylated in CLL [20], and sub-
sequently shown to contribute to CLL progression by
blocking the apoptosis of leukemia cells [10]. Moreover,
since the miR-34 family is a transcriptional target of
TP53, its methylation might lead to the perturbation of
the TP53 tumor suppression pathway. In this report, we
performed a comprehensive methylation study of the
TP53-centered tumor suppressor network by studying
DNA methylation of miR-34a and DAPK1 in addition to
miR-34b/c in a representative cohort of CLL.
Materials and methods
Patient samples
This study has been approved by the Institutional Review
Board of Queen Mary Hospital and written informed
consent has been obtained in accordance with the
Declaration of Helsinki. Diagnostic bone marrow sam-
ples were obtained in 78 CLL patients. Diagnosis of
CLL was made according to the WHO Classification,
which is based on classical morphology, low level of
expression of light-chain-restricted surface immunoglobu-
lin, and dual positivity of CD5 and CD23 in the neoplastic
lymphocytes as demonstrated by flow cytometry [21,22].
There were 51 (65.4%) male and 27 female (34.6%) pa-
tients with a median age of 65 years (range: 37–91 years).
The median presenting lymphocyte count was 18 × 109/l
(range: 10 – 540 × 109/l). Among 70 patients with infor-
mation for Rai staging, there were 42 (60.0%) patients with
limited Rai stage (< stage II) and 28 (40.0%) with advanced
Rai stage (≥ stage II) disease. Of the 48 patients with cyto-
genetic data, 12 (25.0%) carried high/intermediate-risk
cytogenetic aberrations [del (17p), N = 2; del (11q), N = 1;
trisomy 12, N = 9] and 36 (75.0%) carried low/standard-risk cytogenetic alterations [del (13q), N = 11; normal
karyotype, N = 18; other karyotypic changes, N = 7]. The
median overall survival (OS) of the cohort was 69 months.
The median OS of those with Rai stage > 2 and those Rai
stage ≤ 2 were 49 and 111 months respectively (P = 0.006).
Moreover, the median OS for those with or without
high/intermediate-risk karyotype were 28 months and
111 months (P = 0.003). Of these, the miR-34a and
DAPK1 methylation results of 50 patients have previ-
ously been reported [20,23]. Therefore, in this study,
DAPK1 and miR-34a methylation were studied in an
additional 28 diagnostic CLL primary samples.
Cell lines and culture
The CLL cell lines MEC1 and CLL-AAT were purchased
from Deutsche Sammlung von Mikroorganismen und
Zellkulturen Deutsche GmbH (DMSZ) (Braunschweig,
Germany) and American Type Culture Collection
(Manassas, USA) respectively. MEC2, WAC3CD5+
and I83-E95 were kindly provided by Dr John C. Byrd,
Department of Medicine, Ohio State University [24,25].
Moreover, HG3 and 232B4 were kind gifts from Prof.
Anders Rosén, Department of Clinical & Experimental
Medicine, Linköping University [25,26]. Cell lines were
maintained in 90% RPMI 1640 + 10% FBS. Culture media
were supplemented with 50 U/ml penicillin and 50 μg/ml
streptomycin (Invitrogen, Carlsbad, CA, USA), and main-
tained in a humidified atmosphere of 5% CO2 at 37°C.
Methylation-specific polymerase chain reaction (MSP)
DNA was extracted from bone marrow samples of CLL
at diagnosis, the cell lines and 11 normal controls (per-
ipheral blood buffy coats obtained from 5 healthy do-
nors, bone marrow buffy coat from 3 healthy donors,
and CD19 sorted peripheral blood B-cells from 3 healthy
controls) by standard method. The normal controls com-
prised 5 males and 6 females with a median age of 38 years
(range: 25–60 years). Treatment of DNA with bisulfite for
conversion of unmethylated cytosine to uracil (but unaf-
fecting methylated cytosine) was performed with a com-
mercially available kit (EpiTect Bisulfite Kit, QIAGEN,
Hilden, Germany). Details of primers and conditions for
MSP of miR-34b/c, miR-34a and DAPK1 were given in
Table 1. To define the sensitivity of miR-34a M-MSP,
1 μg of methylated control DNA was 10-foldedly serially
diluted in buffer, bisulfite-treated and amplified with
miR-34a M-MSP primers.
Quantitative bisulfite pyrosequencing
DNA was treated with bisulfite and used as template.
Primers for pyrosequencing were used to amplify the
promoter region, which was overlapped with the
amplicon of MSP. Primers were designed using PSQ
Assay Design software (Biostage). Forward primer: 5’-
Table 1 miR-34a, miR-34b/c and DAPK1 MSP Primer sequences and the reaction condition
Gene Forward primer (5’ to 3’) Reverse primer (5’ to 3’) Tm/cycles/MgCl2 References
miR-34a
U-MSP GGGGATGAGGATTAGGATTTT CAAACAAAACACATAAAAACAACA 58°C/35×/1.5 mM [23]
M-MSP GGGGATGAGGATTAGGATTTC ACAAAACGCATAAAAACGACG 58°C/35×/1.5 mM
miR-34b/c
U-MSP TTTTTATTTGTTTTGTTTTGTGTTTGTTTTG CAACTACAACTCCCAAACAATCC 56.5°C/38×/2 mM [27,28]
M-MSP ATTCGTTTCGTTTCGCGTTCGTTTC CGACTACAACTCCCGAACGATCCG 60°C/34×/2 mM
DAPK1
U-MSP GGAGGATAGTTGGATTGAGTTAATGTT CAAATCCCTCCCAAACACCAA 63°C/35×/1.5 mM [20]
M-MSP GGATAGTCGGATCGAGTTAACGTC CCCTCCCAAACGCCGA 63°C/35×/1.5 mM
Abbreviations: M-MSP MSP for the methylated allele, U-MSP MSP for the unmethylated allele, Tm annealing temperature.
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ACCACAATACAATCAACTAATA-3’; condition: 2 mM/
59°C/50X. A stretch of DNA with 12 adjacent CpG di-
nucleotides was pyrosequenced by sequencing primer:
5’-CAACTAATAACACTACCTACA-3’.
5-Aza-2’-deoxycytidine (5-AzadC) treatment
MEC1 cells were cultured in six-well plates at 1 × 106
cells/ml, with 0.5 μM of 5-AzadC (Sigma-Aldrich, St.
Louis, MO, USA) for 5 days. Cells on day 0 and day 5 of
5-AzadC treatment were harvested.
Quantification of miR-34b and reverse transcription-PCR
of DAPK1
According to the respective manufacturer’s instructions,
total RNA was isolated and reversely transcribed using the
mirVana miRNA Isolation Kit. miRNA was quantified by
the TaqMan MicroRNA RT Kit, and TaqMan MicroRNA
Assay Kit as reported [27-29]. RNU48 was chosen as re-
ference for data analysis using the 2-ΔΔCt method [30].
Moreover, for semi-quantitative analysis of DAPK1 expres-
sion, DAPK1 was reversely transcribed by the QuantiTect
Reverse Transcription Kit (QIAGEN, Valencia, CA) [31].
Reverse transcription-PCR primers and PCR condition for
DAPK1 were summarized in Table 2.
Western blot for DAPK1
MEC1, MEC2, 232B4, CLL-AAT and WAC3CD5+ cells
were harvested and then lysed in RIPA buffer (50 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 0.2% SDS, 1% TritonTable 2 Primer sequences and the reaction condition of DAPK
reaction (RT-PCR)
Gene Forward primer (5’ to 3’) Reverse prim
DAPK1 CAGTTTGCGGTTGTGAAGAA CCTGCAACG
GAPDH ACCACAGTCCATGCCATCACT TCCACCACC
Abbreviations: Tm annealing temperature.X-100, 2 mM EDTA). Protein lysates were resolved on
6% SDS-PAGE and electrotransferred onto a 0.2 μm
nitrocellulose membrane (Bio-Rad, Hercules, CA). The
membranes were blocked and incubated with anti-
DAPK1 (1:1000; Sigma-Aldrich, USA) or anti-actin
(1:5000; Sigma-Aldrich, USA) primary antibody at 4°C
overnight. Then membranes were washed three times
and incubated with anti-rabbit horseradish peroxidase
conjugate secondary antibody at room temperature for
1 hour. Protein signals were detected by ECL Prime West-
ern blotting detection reagents (Amersham Biosciences,
Buckinghamshire, UK).
Precursor miR-34b overexpression
Precursor miR-34b (100nM; Ambion) (oligonucleotide
mimic) was transfected into 1 × 106 MEC1 cells using
X-tremeGENE siRNA Transfection Reagent (Roche Diag-
nostics/Roche, Basel, Switzerland), according to the manu-
facturers’ instructions [28]. Non-targeting oligonucleotide
mimic was used as negative control.
Proliferation, viability and cell cycle analyses
To document the tumor suppressor function of miR-
34b, three independent transfections were performed, in
which functional studies including MTT assay, Trypan
blue exclusion assay and the percentage of sub-G1 frac-
tion were performed in triplicate after each transfection.
The MTT method was used to determine cellular prolif-
eration. Cells were cultured in a 96-well microtitre plate
at 2.5 × 104/well in 100 μl of medium. At test time-1 and GAPDH Reverse transcription-polymerase chain
er (5’ to 3’) Tm/cycles/MgCl2 References
AGTTCCAAGAT 53°C/35×/2 mM [31]
CTGTTGCTGTA 60°C/24×/2 mM [23]
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well and incubated for 4 hours, after which 100 μl of di-
methyl sulfoxide (DMSO) was added, and absorbance at
550 nm with reference to 650 nm was measured. Cellularity
viability assay was performed by the Trypan blue dye exclu-
sion assay. For cell cycle analysis, test cells were washed in
phosphate buffered saline (PBS), fixed in cold 70% ethanol
at 4°C overnight, washed twice in PBS, resuspended and in-
cubated in 50 μg/ml PI staining solution with 5 μg/ml
RNase A at 4°C for at least 2 hours, and then analyzed by
flow cytometry (Beckman Coulter Cytomics FC 500).
Statistical analysis
In CLL, correlation between DAPK1, miR-34a and miR-
34b/c methylation status with continuous (mean age,
mean diagnostic haemoglobin (Hb), lymphocyte or platelet
counts at diagnosis) and categorical variables (gender, Rai
stage or high-risk karyotypes) were studied respectively by
Student’s t-test and chi-square test (or Fisher’s exact test).
Moreover, in 50 samples, the methylation of miR-203,
miR-124-1 has been studied [29,32], and the association of
miR-34b/c with the methylation of miR-203 and miR-124-
1 was analyzed by chi-square test. OS is measured from
the date of diagnosis to the date of last follow-up or death.
OS of patients with limited Rai stage (stages 0, I and II)
was compared to those with advanced Rai stage (stages IIIFigure 1 MSP of miR-34b/c, miR-34a and DAPK1 in controls. (A) U- and
control (PC) was completely methylated while all normal controls were comp
blood buffy coat of healthy donors; N6 to N8: CD19 sorted B cells of the perip
healthy donors; PC: Positive control with methylated DNA. (B) Sensitivity of m
1 μg of methylated control DNA was 10-fold serially diluted in buffer, bisulfite
reagent blank: Serial dilution of methylated positive control from 1 to 10-5.and IV). Moreover, OS of patients with high-risk karyo-
types [del (17p), del (11q) or trisomy 12] was compared
with those with standard-risk karyotypes [del (13q),
normal karyotype or other karyotypic changes]. The
mean values of MTT assay, Trypan blue exclusion assay
and sub-G1 fraction in MEC1 cells transfected with precur-
sor miR-34b mimic were compared with negative control
transfected with a scrambled oligo by Student’s t-test. Sur-
vival is plotted by the Kaplan–Meier method and compared
by the log-rank test. All P values were two-sided.
Results
MSP
Controls
None of the 8 normal peripheral blood controls (N1 to
N8) and 3 normal bone marrow controls (N9 to N11)
showed aberrant methylation of miR-34b/c, miR-34a or
DAPK1 (Figure 1A). Expected MSP results (normal DNA:
U-MSP positive/M-MSP negative; methylated DNA: U-
MSP negative/M-MSP positive) were demonstrated in the
positive and negative controls. Moreover, the sensitivity of
miR-34aM-MSP was 10−2 (Figure 1B).
CLL cell lines
The profile of miR-34b/c methylation of 7 CLL cell
lines was shown in Figure 2A. MEC1, 232B4, I83-E95M-MSP of miR-34b/c, miR-34a and DAPK1 showed that the positive
letely unmethylated. MW: Marker; B: Reagent blank; N1 to N5: Peripheral
heral blood from healthy donors; N9 to N11: Bone marrow control of
ethylated-MSP of miR-34a. To define the sensitivity of miR-34a M-MSP,
-treated and amplified with miR-34a M-MSP primers. MW: marker; B:
Figure 2 Methylation of miR-34b/c, miR-34a and DAPK1 in CLL cell lines. (A) In CLL cell lines, MEC1, 232B4, I83-E95 and WAC3CD5+ were
completely methylated and MEC2, HG3 and CLL-AAT were completely unmethylated for miR-34b/c. I83-E95 was completely methylated, MEC1
was partially methylated, but MEC2, 232B4, CLL-AAT, HG3 and WAC3CD5+ were unmethylated for miR-34a. Moreover, MEC1 was completely
methylated, and other six cell lines were unmethylated for DAPK1. (B) Stem-loop qRT-PCR analysis of the mature miR-34b expression in 7 CLL cell
lines. ΔCt, Ct miR-34b-Ct RNU48. (C) In CLL cell lines, MEC1 cells showed no DAPK1 mRNA expression while other six cell lines had detectable
DAPK1 mRNA levels. (D) Sequencing analysis of the semi-quantitative RT-PCR products for the detection of DAPK1. MW: Marker; B: Reagent blank;
N1: Normal donors; NoRT: Negative control without reverse transcriptase; PC: positive control with methylated DNA. (E) Western blot analysis of
DAPK1 in MEC1, MEC2, 232B4, CLL-AAT and WAC3CD5+ cells. WAC3CD5+ cells were used as positive control. Anti-actin protein was regarded as
the endogenous normalizer and the relative DAPK1 protein level was shown in the bottom row.
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34b/c whereas MEC2, HG3 and CLL-AAT were com-
pletely unmethylated. Quantitative bisulfite pyrosequencing
confirmed the methylation statuses (MM and UU) of
CLL cell lines detected by MSP (Additional file 1: Table S1
and Figure S1A-C). On the other hand, miR-34a was
completely methylated in I83-E95, partially methylatedin MEC1 and completely unmethylated in MEC2, 232B4,
CLL-AAT, HG3 and WAC3CD5+ (Figure 2A). DAPK1 was
completely methylated in MEC1 but completely unmethy-
lated in other six CLL cell lines (Figure 2A).
Moreover, in order to confirm the association of miR-
34b/c expression and methylation in CLL cell lines, the
mean miR-34b expression and miR-34b/c methylation
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sults showed the mean miR-34b expression in completely
methylated CLL cell lines (MEC1, 232B4, I83-E95 and
WAC3CD5+) was significantly lower than that of unmethy-
lated MEC2, HG3 and CLL-AAT, and hence a higher (ΔCt)
(P = 0.05) (Figure 2B). Furthermore, in CLL cell lines,
complete methylation of DAPK1 in MEC1 cells showed ab-
sence of DAPK1mRNA expression while other six cell lines
without DAPK1 methylation showed detectable DAPK1
mRNA levels (Figure 2C). The sequence analysis of semi-
quantitative RT-PCR of DAPK1 was shown in Figure 2D.
Western blot analysis also revealed marked downregulation
of DAPK1 protein expression in MEC1 when compared
with cells with absence of DAPK1 methylation including
MEC2, 232B4, CLL-AAT, WAC3CD5+ cells (Figure 2E).Primary samples at diagnosis
(I) miR-34 family
miR-34b/c methylation was found in 14 of 78 (17.9%)
patient samples at diagnosis (Figure 3A). No correlation
was demonstrated between miR-34b/c methylation and the
diagnostic Hb level (P = 0.76), lymphocyte count (P = 0.51)Figure 3 Promoter methylation of miR-34b/c, miR-34a and DAPK1 in C
in CLL primary samples. (B) U-/M-MSP analysis of miR-34a methylation in C
CLL primary samples. MW: Marker; B: Reagent blank; N1: Normal donors; S:or platelet count (P = 0.65). There was no significant asso-
ciation of miR-34b/c methylation with age (P = 0.97), gen-
der (P = 0.76), advanced Rai stage (≥ stage 2) (P = 0.75) and
high-risk karyotypic aberrations (P = 0.66). The median OS
of CLL patients with and without miR-34b/c methylation
were 51 and 69 months respectively (P = 0.77). In addition,
miR-34a methylation was present only in 2 (2.6%) of CLL
samples (Figure 3B).
Moreover, methylation status of miR-203, miR-34a and
miR-124-1 was available in 50 patients. miR-34b/c methy-
lation was found to be associated with the methylation
of miR-203 (P = 0.012) and miR-34a (P = 0.03), but not
miR-124-1 (P = 0.06).
(II) DAPK1
DAPK1 was found in 27 of 78 (34.6%) patients at diag-
nosis (Figure 3C). Apart from the association with ad-
vanced age (P = 0.04), the methylation status of DAPK1
was not associated with other clinical demographics
including gender (P = 0.46) and advanced Rai stage (≥ stage
2) (P = 0.30), high-risk karyotypic aberrations (P = 0.73),
diagnostic Hb level (P = 0.67), lymphocyte count (P = 0.51)
or platelet count (P = 0.59). The median OS for CLLLL primary samples. (A) U-/M-MSP analysis of miR-34b/c methylation
LL primary samples. (C) U-/M-MSP analysis of DAPK1 methylation in
Sample at diagnosis; PC: Positive control with methylated DNA.
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and 68.88 months respectively (P = 0.98). The methylation
status of DAPK1 was not associated with that of miR-34b/c
(P = 0.99), miR-34a (P = 0.12), miR-124a (P = 0.40) or miR-
203 (P = 0.13).
Moreover, we performed MSP of miR-34b/c, miR-34a
and DAPK1 in both peripheral blood and bone marrow
samples of patients, in whom both peripheral blood and
bone marrow were available. Concordant MSP results of
miR-34b/c, miR-34a and DAPK1 between bone marrow
cells and peripheral blood cells were demonstrated, and
hence both peripheral blood and marrow tumor cells are
valid for methylation study (Figure 4A-C).Methylation profiling of miR-34a, miR-34b/c or DAPK1 in
primary samples
Among the 78 patients, apart from 53.8% (42/78) of pa-
tients who did not show methylation of any of these
three genes, 39.7% (31/78), 3.8% (3/78) and 2.6% (2/78)Figure 4 Comparison of the MSP results of miR-34b/c, miR-34a and D
of the same CLL patients. U-/M-MSP analysis of (A) miR-34b/c, (B) miR-34
peripheral blood cells. MW: Marker; B: Reagent blank; N2: Normal bone mar
marrow cells of CLL sample at diagnosis; Patient PB: Peripheral blood cellsof patients had methylation of one, two or all of the
three genes respectively. Overall, 46.2% (36/78) had
methylation of at least one of these three genes.
5-AzadC treatment of MEC1 cells
MEC1 cells were completely methylated for miR-34b/c.
5-AzadC demethylation treatment of MEC1 cells led to
the demethylation of miR-34b/c and the emergence of
U-MSP signal on day 5 (Figure 5A and Additional file 1:
Figure S1D), with the re-expression of mature miR-34b
shown by TaqMan stem-loop quantitative RT-PCR
(Figure 5B).
Effect of miR-34b overexpression in MEC1 cells
miR-34b was completely methylated for the MEC1 cells,
and hence under-expressed. Upon transfection of pre-
cursor miR-34b mimic into MEC1 cells, overexpression
of mature miR-34b was demonstrated by TaqMan stem-
loop quantitative RT-PCR (Figure 6A). When compared
with negative control transfected with a scrambled oligo,APK1 between the bone marrow cells and peripheral blood cells
a and (C) DAPK1 on 5 CLL primary samples of both bone marrow and
row control; N3: Normal peripheral blood control; Patient BM: Bone
of CLL sample at diagnosis; PC: Positive control with methylated DNA.
Figure 5 Effect of 5-Aza-2’-deoxycytidine (5-AzadC) treatment on MEC1 cells. (A) U- /M-MSP analysis of miR-34b/c promoter methylation
status. (B) stem-loop RT-qPCR analysis of the mature miR-34b expression. 5-AzadC treatment led to the progressive demethylation of miR-34b/c
promoter, and re-expression of the mature miR-34b in MEC1 cells. MW: Marker; B: Reagent blank; N: Normal donors; PC: Positive control with
methylated DNA; D0: Day 0; D5: Day 5 culture in 0.5 μm 5-AzadC.
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duction of cellular proliferation by MTT assay (P = 0.03,
Figure 6B), a 10% increase of dead cells measured by
Trypan blue exclusion assay (P = 0.02, Figure 6C), in
addition to a 12% increase of cells in sub-G1 phase using
propidium iodide staining (P = 0.02, Figure 6D), suggest-
ing that miR-34b played a tumor suppressive role in CLL
cells.Figure 6 Over-expression of miR-34b in CLL cells. MEC1 cells, complete
mimic or scrambled control oligos. (A) Stem-loop RT-qPCR analysis of matu
of CLL cells in response to overexpression of miR-34b was measured by MT
assay. (D) The percentage of apoptotic cells (sub-G1 cells) was measured b
means from each of the 3 experiments performed in triplicate ± standard dDiscussion
Despite the retrospective nature, our cohort was repre-
sentative of CLL in view of the prolonged survival, and
the expected adverse impact of advanced Rai stage and
high-risk karyotype. It is ideal to perform pyrosequencing
of primary samples. Unfortunately, only buffy coat has
been collected from the primary marrow samples without
cell selection. Given that the sensitivity of M-MSP ofly methylated for miR-34b, were transfected with mature miR-34b
re miR-34b expression at 48 hrs after transfection. (B) Cell proliferation
T assay. (C) Cellular death was measured by Trypan blue exclusion
y the Propidium iodide staining. Values represented the average of the
eviation.
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infiltration ranged from 36% to 95% (median: 64%), our
results are still valid even without CD19 cell sorting of
primary samples. Moreover, in patients in whom both
peripheral blood and bone marrow buffy coats were
available, concordant MSP results for miR-34b/c, miR-34a
and DAPK1 were demonstrated, and hence both periph-
eral blood and bone marrow were valid for methylation
analysis. Based on these experiments, several observations
were made from the study.
Firstly, miR-34b/c methylation is tumor-specific as illus-
trated by the absence of methylation in normal peripheral
blood and bone marrow cells, but complete methylation
in 4 of the 7 CLL cell lines. Moreover, the expression of
miR-34b was also correlated inversely with the methyla-
tion status, with low miRNA expression in completely
methylated cell lines and significantly higher expression
in completely unmethylated cell lines. Furthermore,
after the 5-AzadC treatment of MEC1 cells, the appear-
ance of U-MSP signal, and hence demethylation of miR-
34b/c promoter, was associated with mature miR-34b
re-expression. Therefore, hypermethylation of miR-34b/
c is prevalent in CLL cell lines, resulting in reversible
miRNA silencing.
Secondly, miR-34b/c is a tumor suppressor miRNA in
CLL. This is demonstrated by the inhibition of cell prolifer-
ation and increase of cellular death upon over-expression
of miR-34b in MEC1 cells possessing complete methylation
of miR-34b/c. Given the increasing evidence that TSGs are
silenced by gene hypermethylation, promoter hypermethy-
lation, together with inactivating gene mutation or deletion
of the other allele may serve as one of the two hits of
Knudson’s hypothesis [2,33]. Moreover, miR-34b/c is local-
ized to 11q23 and hence, it is tempting to postulate that
miR-34b/c methylation might cooperate with del (11q) to
inactivate both alleles of miR-34b/c, thereby fulfilling the
Knudson’s hypothesis [34]. However, in our samples, there
was only one case of del (11q) to verify this hypothesis.
In contrast to miR-34a, which was rarely hypermethy-
lated in CLL, miR-34b/c was frequently methylated
in CLL samples at diagnosis. However, there was no
significant association between the methylation status of
miR-34b/c with clinical parameters, such as age, gender,
diagnostic Hb, lymphocyte or platelet count, Rai stage,
or survival. However, it has been reported that the down
regulation of miR-34 family is involved CLL with an
aggressive course [35]. In view of the small number of
samples in our cohort, the impact of miR-34b/c methyla-
tion on survival warrants a larger scale study. Neverthe-
less, infrequent miR-34a methylation was also contrasted
with the frequent miR-34a methylation in many epithelial
cancers [23,36].
Frequent methylation of DAPK1 was also observed in
our patients, and 46.2% (36/78) had methylation of eitherDAPK1 or miR-34b/c. Therefore, despite infrequent TP53
deletion or mutation in CLL at diagnosis, frequent
miR-34b/c or DAPK1 methylation is implicated in the
disruption of the TP53-centered tumor suppression
network. This is particularly important as TP53 is also
found to be haploinsufficient in carcinogenesis as in-
activation of only one TP53 allele is sufficient to pre-
dispose to carcinogenesis [37].
Finally, an interesting observation was that methylation
of miR-34b/c (localized at chromosome 11q23) was associ-
ated with methylation of miR-203 (localized at 14q32),
similar to the association between miR-203 methylation
with miR-34a, miR-124a, miR-196b and miR-129-2 methy-
lation in non-Hodgkin’s lymphoma [29,38]. miR-34b/c and
miR-203 have been shown independently to target CREB
mRNAs [39,40]. As a transcription factor, CREB can up-
regulate the expression of multiple genes involved in the
cell cycle progression (CCNA1, CCNB1 and CCND1) and
survival (BCL2 and NFκB1) [39]. Therefore, concomitant
methylation of both miR-203 and miR-34b/c might collab-
orate in the de-repression of CREB-related cell prolifera-
tion and survival, contributing to carcinogenesis.
Conclusion
In conclusion, miR-34b/c methylation is a tumor sup-
pressor miRNA frequently methylated in CLL. miR-34b/
c methylation is associated with reversible miRNA silen-
cing. Despite the infrequent occurrence of inactivating
TP53 mutation in CLL at diagnosis, miR-34b/c methyla-
tion, together with DAPK1 methylation, is implicated in
the perturbation of the TP53-centered tumor suppressor
network. Finally, the implication of association of miR-
34b/c methylation with that of miR-203 warrants further
analysis.
Additional file
Additional file 1: Table S1. Average percent methylation for miR-34b/c
in 7 CLL cell lines by pyrosequencing. Figure S1. Quantitative bisulfite
pyrosequencing analysis of miR-34b/c. The pyrograms showed the
methylation intensity on a stretch of 12 neighboring CpG dinucleotides of
(A) Normal control without methylation and positive control with
methylated DNA, (B-C) CLL cell lines with defined MSP methylation status
(MM and UU) and (D) MEC1 cells before and after 5-azadC treatment.
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